CONNECT WITH US
HealthTech

HealthTech

Lingering CAR T cells may be the cause of serious gut complication after myeloma therapy

Medical Xpress logo

Published on

Add as a preferred source on Google
Lingering CAR T cells may be the cause of serious gut complication after myeloma therapy

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their bloodstream, according to new research from The University of Texas MD Anderson Cancer Center.

The findings, published in Nature Medicine, may help clinicians better diagnose and treat affected patients earlier.

Immune effector cell-associated enterocolitis (IEC-EC) is a rare but serious gastrointestinal side effect that can occur in patients after CAR T cell therapy. The complication is associated with severe clinical outcomes, including prolonged hospitalization, need for intensive nutritional support and increased mortality.

In the study, patients treated with the CAR T cell therapy ciltacabtagene autoleucel (cilta-cel) who developed IEC-EC had dramatically higher levels of long-term CAR T cell persistence in their blood—more than 100 times higher, on average, than in patients who did not develop the condition.

"Our study found that IEC-EC is not just inflammation of the gastrointestinal tract, but it is a distinct CAR T cell therapy–driven immune cell disorder," said the study's corresponding author Mark Hamilton, M.D., assistant professor of Lymphoma & Myeloma.

"By understanding the biology behind this complication, we can improve recognition of the syndrome and develop more effective strategies to monitor and treat patients."

Researchers analyzed nine cases of IEC-EC occurring among 158 patients treated with cilta-cel. IEC-EC occurred in approximately 5% of patients who received treatment.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.